TABLE 1.

Second messenger pathways

Cells were treated with the indicated inhibitor prior to measuring the increase in peak response to NMDA (300 µM) produced by PregS (100 µM). Treatment conditions were as follows: U-73122/U-73343, 1 hour, 20 µM in Barth’s solution plus 0.4% DMSO; PTx, 50 nl injection of 500 pg of PTx in 5 mM Tris, 0.05 mM EDTA, 0.015% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS), pH 8.

Treatment	Target	Total Potentiation	Rapid Potentiation	Delayed Potentiation
		%	%	%
Vehicle		203 ± 15	68 ± 4	76 ± 7 (15)a
PTx	Gi/Go	140 ± 13	72 ± 4	40 ± 6 (13)*
U-73343	Inactive control	182 ± 17	62 ± 6	75 ± 7 (6)
U-73122	PLC	83 ± 6	60 ± 5	14 ± 5 (8)**

^aThe number of oocytes is given in parentheses.

^*P < 0.001; **P < 0.005 [statistically significant versus vehicle (2-tailed t test)]